Mutations disrupting the reading frame of the ~2.4 Mb dystrophin-encoding DMD gene cause a fatal X-linked muscle-wasting disorder called Duchenne muscular dystrophy (DMD). Genome editing based on paired RNA-guided nucleases (RGNs) from CRISPR/Cas9 systems has been proposed for permanently repairing faulty DMD loci. However, such multiplexing strategies require the development and testing of delivery systems capable of introducing the various gene editing tools into target cells. Here, we investigated the suitability of adenoviral vectors (AdVs) for multiplexed DMD editing by packaging in single vector particles expression units encoding the Streptococcus pyogenes Cas9 nuclease and sequence-specific gRNA pairs. These RGN components were customized to trigger short-and longrange intragenic DMD excisions encompassing reading frame-disrupting exons in patient-derived muscle progenitor cells. By allowing synchronous and stoichiometric expression of the various RGN components, we demonstrate that dual RGN-encoding AdVs can correct over 10% of target DMD alleles, readily leading to the detection of Becker-like dystrophin proteins in unselected muscle cell populations. Moreover, we report that AdV-based gene editing can be tailored for removing mutations located within the over 500-kb major DMD mutational hotspot. Hence, this single DMD editing strategy can in principle tackle a broad spectrum of mutations present in more than 60% of patients with DMD.
. These studies provide a strong rationale for developing DMD therapeutic strategies based on RGN multiplexes. However, more research is needed especially for achieving simultaneous, uniform and efficient introduction of all nuclease components into target cells.
In the present work, we sought to investigate the feasibility and suitability of using "all-in-one" adenoviral vectors (AdVs) for delivering RGN multiplexes designed for removing single or multiple exons from defective DMD alleles. Following AdV transductions of patient-derived muscle progenitor cells, we report that these NHEJ-mediated gene editing strategies result in efficient DMD reading frame restoration and yield readily detectable dystrophin synthesis in muscle cells differentiated from unselected target cell populations. Notably, we demonstrated that "all-in-one" AdVs can mediate the removal of mutations located within the over 500-kb major DMD mutational hotspot allowing for tackling more than 60% of the registered DMD mutations 5 via a single viral-based gene editing strategy. Furthermore, we tested side-by-side DMD editing based on "all-in-one" AdV delivery of dual and single RGN complexes. The latter strategies are customized to correct specific DMD mutations via NHEJ-mediated reading frame resetting and DNA-borne exon skipping 20 . We demonstrate that AdVs encoding single or dual RGN complexes can lead to DMD repair and de novo dystrophin protein synthesis without having to resort to cell selection schemes. Collectively, this study establishes AdVs as a versatile and powerful platform for the delivery of RGN multiplexes into therapeutically relevant cells.
Results
Packaging RGN multiplexes in single AdV particles. We started by investigating the suitability of AdV particles for packaging DNA coding for Cas9 and gRNA pairs targeting intronic DMD sequences. To this end, we selected RGN complexes customized to trigger short-and long-range intragenic DMD excisions after the activation of the NHEJ pathway 20 . In particular, the gRNA pair gIN52 and gIN53 was designed to induce a short, mutation-specific, DMD excision spanning exon 53. Next to this, the gRNA pair gIN43 and gIN54 was customized to tackle a large range of DMD mutations by triggering DSB formation in introns 43 and 54 flanking the major DMD mutational hotspot. Thus, in the current work, we generated AdV.Cas9
IN52. IN53 and AdV.Cas9 IN43.IN54 particles containing expression units encoding the aforementioned gRNA pairs and the S. pyogenes Cas9 protein (Fig. 1a) . Importantly, these second-generation (i.e. E1-and E2A-deleted) AdVs display apical fiber motifs from adenovirus serotype-50 (F 50 ) (Fig. 1a) . In contrast to fibers from prototypic adenovirus serotype-5, that bind the coxsackievirus-adenovirus receptor (CAR), the F 50 motifs recognize the cellular receptor CD46 instead. This allows fiber-modified AdVs to bypass the absence of CAR on the surface of therapeutically relevant cells, including human muscle progenitor cells and non-muscle cells with myogenic capacity 20, [26] [27] [28] . After rescuing, propagating and purifying the dual RGN-encoding AdV particles (i.e. AdV.Cas9
IN52. IN53 and AdV.Cas9 ), we determined that their functional titers and genome copies-to-infectious units ratios were in the range of those of isogenic AdV controls. These controls encode exclusively Cas9, an irrelevant gRNA or encode Cas9 together with a single DMD-targeting gRNA (Fig. 1b) . In addition, restriction fragment length analysis was performed on DNA isolated from purified AdV.Cas9
IN52.IN53 and AdV.Cas9 IN43.IN54 particles. This assay revealed neither large sequence rearrangements nor deletions indicating that both vector genomes were packaged intact ( Supplementary Fig. S1 ). These data demonstrate that tandem gRNA and Cas9 expression units can be stably maintained during the rescue and propagation of AdV particles leading to the packaging of full-length recombinant vector genomes.
"All-in-one" AdV particles achieve DMD repair through short-range, single-exon, excision. To investigate AdV-based DMD editing by targeted single-exon excision, we used the AdV.Cas9
IN52.IN53 to transduce patient-derived myoblasts lacking exons 45 through 52 (DMD.Δ 45-52). This defective genotype can be tackled by the permanent chromosomal excision of exon 53 since the resulting DNA template generates in-frame mRNA transcripts (Fig. 2a) . Of note, approximately 8% to 10% of disrupted DMD reading frames identified in the population with DMD can be fixed by this approach 5, 29 .
To start DMD editing experiments, DMD.Δ 45-52 myoblasts were either mock-transduced or were transduced with AdV.Cas9
IN52.IN53 at MOIs of 25 and 50 IU/cell. At 7 days post-transduction, a qPCR assay designed for quantifying the DNA junctions generated after the simultaneous expression of Cas9:gIN52 and Cas9:gIN53 . The AdV.gRNA S1 and AdV.Cas9, expressing exclusively an irrelevant gRNA and Cas9, respectively, served as controls. The AdV.Cas9 EX51 and AdV.Cas9 EX53 particles code for Cas9:gEX51 and Cas9:gEX53 complexes, respectively. The target sites of Cas9:gEX51 and Cas9:gEX53 complexes are located in exon 51 and exon 53 of the DMD locus, respectively. AdV.Cas9
IN52.IN53 and AdV.Cas9 IN43.IN54 deliver a pair of gRNA cassettes together with a Cas9 transcriptional unit. The gRNAs gIN52 and gIN53 address the Cas9 nuclease to DMD sequences in intron 52 and intron 53, respectively; the gRNAs gIN43 and gIN54 target the same nuclease to sequences located in intron 43 and intron 54, respectively. All vectors deployed in this study were isogenic in the sense that they were all assembled on the basis of a second-generation (i.e. E1-and E2A-deleted) AdV backbone coding for chimeric fibers (F 50 ) consisting of basal domains from human adenovirus serotype-5 and apical shaft and knob motifs from human adenovirus serotype-50. Each gRNA expression unit is under the transcriptional control of RNA Pol-III promoter (i.e. U6) and terminator sequences, whereas the Cas9 ORF is under the transcriptional control of the human PGK-1 promoter (PGK) and the simian virus 40 polyadenylation signal (SV40). Ψ , human adenovirus serotype-5 packaging signal; Ad L-ITR and Ad R-ITR, "left" and "right" adenoviral inverted terminal repeat, respectively; RF, reading frame (b) Ratios of genome copies (GC) to infectious units (IU). The GC and IU concentrations in purified preparations of the indicated AdVs were determined by using fluorometric and TCID 50 
Cas9
EX53 delivers a single Cas9:gEX53 complex customized to induce DSBs at a sequence in exon 53, which trigger NHEJ in generating indels that disrupt splicing motifs or shift the reading frame to the proper coding sequence. The resulting DNA-borne exon skipping and reading frame resetting events repair the defective DMD locus in DMD.Δ 45-52 cells 20 . After triggering myoblast differentiation, western blot analysis revealed the presence of Becker-like dystrophin proteins in cultures of myotubes whose progenitors had undergone AdV.Cas9 EX53 and AdV.Cas9
IN52.IN53 transductions (Fig. 2c ). As expected, DMD myoblasts exposed to the control vector AdV. gRNA S1 did not yield detectable levels of dystrophin once differentiated into myotubes (Fig. 2c) . Importantly, based on the relative intensities of the western blot signals diagnostic for dystrophin, the levels of de novo dystrophin protein synthesis resulting from AdV.Cas9
IN52.IN53 transductions were not inferior to those achieved by the isogenic AdV.Cas9 EX53 (Fig. 2c) .
"All-in-one" AdV particles achieve DMD repair through long-range, multi-exon, excision. To broaden the potential applicability of AdV-based DMD editing, we have investigated the suitability of AdV. Cas9 IN43.IN54 for chromosomal removal of sequences framing the major DMD mutational hotspot. To this end, we deployed patient-derived myoblasts with two different DMD genotypes (i.e. DMD.Δ 48-50 and DMD.Δ 45-52) (Fig. 3a) . These and all the other faulty genotypes nested within the major DMD mutational hotspot region can, in principle, be tackled by AdVs encoding Cas9:gIN43 and Cas9:gIN54 complexes since these RGNs generate DSBs at their cognate sequences in intron 43 and intron 54, respectively. The NHEJ-mediated end-to-end ligation of the resulting chromosomal termini, and concomitant excision of the intervening DNA, is expected to rescue dystrophin synthesis as splicing of exon 43 to exon 55 generates in-frame RNA transcripts (Fig. 3a) .
Therefore, we performed DMD editing experiments in which DMD.Δ 48-50 and DMD.Δ 45-52 myoblasts were either mock-transduced or were transduced with AdV.Cas9
IN43.IN54 at MOIs ranging from 5 to 75 IU/cell. At 7 days post-transduction, a PCR assay with primers flanking the expected genomic excision, readily led to the detection of amplicons diagnostic for the de novo generated junction Δ 44-54 exclusively in AdV.Cas9 IN43.IN54 -transduced myoblast populations ( Supplementary Fig. S2 ). Importantly, a qPCR assay analogous to that used for measuring single-exon deletions (Fig. 2b) , revealed a clear AdV.Cas9
IN43.IN54 dose-dependent increase in DMD editing frequencies in DMD.Δ 48-50 and DMD.Δ 45-52 target cell populations (Fig. 3b) . The fractions of DMD-edited myoblasts ranged from a minimum of 3% to a maximum of 18% (Fig. 3b) . Interestingly, these gene correction levels were similar to those achieved in parallel transduction experiments in which isogenic AdV. Cas9 EX51 particles were used instead for targeted DMD repair in DMD.Δ 48-50 myoblasts ( Supplementary Fig. S3 ). In contrast to AdV.Cas9
, isogenic AdV.Cas9 EX51 works analogously to AdV.Cas9 EX53 in that it delivers a single RGN complex (i.e. Cas9:gEX51) customized to repair the defective DMD locus via DNA-borne exon skipping and reading frame resetting 20 . (Fig. 3c) . Consistent with the large sizes of the excised chromosomal DNA fragments, the de novo generated dystrophin variants were smaller than those expressed from differentiated wild-type myoblasts (Fig. 3c) . Importantly, in line with the DMD editing frequencies at the DNA level, the amounts of dystrophin molecules induced by AdV.Cas9
IN43.IN54 were similar to those achieved by using the isogenic vector AdV.Cas9 EX51 (Fig. 3c ). As expected, parallel transduction experiments in which the control vector AdV.gRNA S1 was used, did not lead to detectable amounts of dystrophin (Fig. 3c) .
To complement the previous data, myotube cultures parallel to those processed for western blot analysis, were subjected to dual-color immunofluorescence microscopy. This assay permits the simultaneous detection of dystrophin and β -dystroglycan, a key component of the DAPC. Consistent with the western blot results, the immunofluorescence microscopy data confirmed rescue of dystrophin synthesis in DMD.Δ 48-50 and DMD.Δ 45-52 myotubes whose progenitors had been exposed to AdV.Cas9 IN43.IN54 or AdV.Cas9 EX51 (Fig. 4) . Furthermore, a degree of AdV.Cas9
IN43.IN54 dose-dependent increase in dystrophin amounts could be discerned corroborating the data retrieved by qPCR (Fig. 3b) . Importantly, co-localization of dystrophin-and β -dystroglycan-specific signals could be detected in DMD-edited myotubes (Fig. 4) . These data suggest the stabilization and proper assembly of β -dystroglycan at the plasma membrane, likely owing to its linkage to the cysteine-rich domains of the de novo synthesized dystrophin molecules.
Taken our data together, we demonstrate that DMD editing based on AdVs encoding RGN multiplexes induces robust synthesis of Becker-like dystrophins in unselected muscle cell populations. Moreover, notwithstanding differences specific to each of the experimental settings, namely the use of different gRNAs, our data suggest that AdV delivery of two RGNs can yield DMD repair levels similar to those achieved by using AdV transfer of single, mutation-specific, RGNs.
Discussion
Sequence-specific programmable nucleases have dramatically accelerated progress in genome editing and are opening up alternative therapeutic options for tackling acquired and inherited disorders, including DMD 30 . Yet, advancing the testing and application of DMD editing requires, amongst other developments, improved methods for delivering the necessary, and often sizable, molecular tools into target cells. The delivery issue is even more critical in the case of multiplexing strategies since these require simultaneous introduction of different nuclease complexes into target cell nuclei 13 . In this regard, the integration of viral vectors and RGNs, as bona fide gene delivery vehicles and versatile programmable nucleases, respectively, has the potential to facilitate and broaden the applicability of multiplexing strategies for DMD editing in ex vivo and in vivo settings 31 . AdVs constitute appealing delivery systems owing to their large packaging capacity, strict episomal nature and fast kinetics of transgene expression in dividing and post-mitotic target cells 32, 33 . Indeed, previous work carried out in our laboratory has shown that AdVs yield high-level and transient expression of transcription activator-like effector nucleases and Cas9 nucleases in clinically relevant cell types, including muscle progenitor cells and non-muscle cells with myogenic capacity 20, 28, 34 . In the current work, we have demonstrated that "all-in-one" dual RGN-encoding AdVs trigger short-and long-range removal of DMD segments encompassing out-of-frame sequences. Both of these gene editing strategies resulted in DMD reading frame restoration and ensuing dystrophin detection in target cell populations without the need for implementing expedients to select DMD-edited cells or nuclease-exposed cell fractions. Moreover, the frequencies of DMD repair achieved by AdV delivery of RGN multiplexes for long-range intragenic deletions were similar to those obtained by AdV transfer of single RGNs for mutation-specific reading frame resetting and DNA-borne exon skipping 20 . The excision of the large DMD segment encompassing exons 44 through 54, shortens the internal rod-shaped portion of dystrophin composed of a series of spectrin-like repeats interrupted by proline-rich segments called hinges 35 . This internal dystrophin portion is, to a certain degree, dispensable as indicated by the fact that the vast majority of the in-frame deletions causing BMD are also located between exon 45 and exon 55 (ref. 36) . In this regard, large in-frame DMD deletions reducing the length of the rod-shaped portion of dystrophin have been linked to BMD phenotypes that are milder than those caused by certain shorter deletions [37] [38] [39] . For instance, it has been shown that extensive in-frame deletions removing hinge 3 (i.e. exons 50-51) correlate with milder BMD phenotypes when compared to smaller deletions that preserve hinge 3 37 . Presumably this is the result of the altered combination of primary amino acid sequences impacting the higher-order structures of dystrophins.
The amenability of RGN multiplexing for inducing exon deletions and thereby rescuing dystrophin synthesis is also supported by a recent cluster of studies involving experiments in the mouse model DMD mdx whose mild dystrophic phenotype is caused by a premature stop codon in Dmd exon 23 (refs. 22-25) . In particular, intramuscular co-injection of a pair of conventional serotype-5 AdVs encoding Cas9 and gRNAs, resulted in the excision of Dmd exon 23 and dystrophin protein synthesis in transduced myofibers 22 . In other studies, systemic and local co-injections of pairs of rAAVs encoding gRNAs and either S. pyogenes Cas9 or the smaller orthologue Staphylococcus aureus Cas9 (SaCas9), equally led to the excision of Dmd exon 23 and restoration of dystrophin synthesis in transduced striated muscles [23] [24] [25] . Together, these studies provided proof-of-concepts for in vivo muscle-directed gene repair based on viral vector delivery of RGN multiplexes. However, conventional serotype-5 AdVs have a reduced tropism for human muscle progenitor cells and non-muscle cells with myogenic capacity 26, 27 , while the limited cargo of rAAVs (i.e. ~4.7 kb) restricts the flexibility with which dual RGN-encoding rAAVs can be constructed (e.g. inclusion of sizable constitutive or muscle-specific promoters). In addition, "all-in-one" rAAVs encoding SaCas9 together with gRNA pairs appeared to yield lower frequencies of targeted DNA manipulations when compared to those resulting from rAAVs encoding SaCas9 and gRNA molecules separately 25 . The repair of defective DMD alleles via RGN multiplexing has been further validated in patient-derived myoblasts 19, 20 and human iPSCs 21 . In addition, these studies demonstrated that RGN multiplexing can induce large DMD excisions, generating internally truncated, but functional, dystrophins [19] [20] [21] . However, the very low efficiencies in deleting these large chromosomal segments achieved by using non-viral delivery methods, required the implementation of selection schemes and clonal analysis for the isolation of DMD-edited cells 19, 21 . In contrast, here we report that generating targeted, long-range, DMD deletions by "all-in-one" AdV transduction of RGN multiplexes, results in the direct, selection-free, detection of de novo dystrophin proteins in bulk target cell populations. The delivery of dual RGN complexes by single AdV particles presumably assures that the various nuclease components are present in target cell nuclei at the same time, in high amounts and at a fixed stoichiometry. The synchronous generation of the paired chromosomal DSBs maximizes the chance that end-to-end ligation of the distal chromosomal termini results in the deletion of the intervening sequence. We showed that dual RGN-encoding AdVs induce short-and long-range genomic deletions correcting over 10% of defective DMD alleles.
Studies in severely dystrophic mouse models indicate that dystrophin amounts as low as 4% of the wild-type level confer a clear improvement in survival and motor function 40, 41 . Hence, if low to moderate levels of dystrophin can equally benefit patients with DMD, therapeutic gene correction will be mostly dependent on delivering in a safe manner gene-edited myogenic cells or gene-editing vector particles to large portions of the striated musculature 31 . Towards clinical translation, the use of fiber-modified "all-in-one" AdVs encoding single or dual RGNs will permit testing DMD editing strategies in human muscle progenitor cells and non-muscle cells with myogenic capacity 42, 43 , harboring mutations which are not represented in current animal models 44 . These experiments are expected to contribute to assessing intended and unwanted genome-modification events caused by the interaction of specific DMD editing reagents with the human genome. The present research should also profit from and build upon the development of sensitive and unbiased assays for genome-wide DSB detection 45, 46 .
In conclusion, we have demonstrated that AdVs encoding RGN multiplexes designed to remove a single exon or the major DMD mutational hotspot offer a flexible and robust NHEJ-mediated DMD repair strategy. This research is expected to facilitate the screening and testing of genetic therapies involving the in situ repair of defective DMD loci in patient-own cells.
Materials and Methods

Cells. The human cervix carcinoma HeLa cells (American Type Culture Collection) and the E1-and E2A-
complementing AdV packaging cell line PER.E2A were cultured as previously described 20, 47 . The origin of and the cultures conditions for the human myoblasts harboring DMD intragenic deletions Δ 48-50 or Δ 45-52 or the wild-type DMD genotype, herein referred to as DMD.Δ 48-50, DMD.Δ 45-52 and WT, respectively, have also been detailed elsewhere 48 . The various cell batches used in this study were mycoplasma-free.
gRNAs design and validation. The design and validation of the gRNAs, whose expression is controlled by the human U6 RNA polymerase III promoter, have been described before 20 . The gRNA cassettes gI43, gI52, gI53 and gI54.2 (hereinafter named gIN43, gIN52, gIN53 and gIN54, respectively) target sequences present in DMD introns 43, 52, 53, and 54, respectively. The gRNA paired cassettes gIN52/gIN53 and gIN43/gIN54 were employed to trigger short-and long-range intragenic DMD excisions, respectively. The individual gRNA cassettes gE51.2 and gE53 (hereinafter named gEX51 and gEX53, respectively), used as references for DMD repair based on the delivery of single RGN complexes, target DMD sequences located in exon 51 and 53, respectively.
The DNA target sequences of each gRNA are listed in Supplementary Table S1 .
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Plasmids. Standard recombinant DNA techniques were applied for the construction of the various AdV transfer constructs and qPCR standard-curve plasmids 49 . To generate the standard-curve plasmids for the qPCR assays, genomic DNA from cell populations containing RGN-induced DMD deletions, were subjected to PCR for amplifying DNA sequences encompassing the de novo generated junctions. The primer sequences, the PCR mixture compositions and the cycling parameters are specified in the Supplementary Tables S2 and S3 . Agarose gel electrophoresis in 1× TAE buffer was performed for the detection of the resulting PCR products. Next, PCR amplicons were purified using the JETquick Gel Extraction Spin kit (Genomed), according to the manufacturer's recommendations. Subsequently, purified PCR products were cloned into the pJET1.2/blunt backbone using the CloneJET PCR cloning Kit (Thermo Scientific), according the manufacturer's instructions. These maneuvers gave rise to plasmids AV31_jDEL.I52-I53 and AV24_jDEL.I43-I54. The structural integrity of the generated plasmids was assessed by restriction fragment length analysis. The nucleotide sequences of the inserts were confirmed by Sanger sequencing (BaseClear, Leiden, the Netherlands). Similarly, conventional recombinant DNA techniques were applied to generate AL05_pDMD. This construct, containing DNA sequences from DMD intron 43, was used for generating standard curves for the quantification of a control genomic region via qPCR assays. The complete DNA sequence of AL05_pDMD is presented in Supplementary Table S4 . 20, 28 . The titers of the purified AdV stocks expressed in genome copies per ml (GC/ml) and infectious units per ml (IU/ml) together with their ratios are listed in Supplementary Table S5 . The former and latter titers were determined by using the QuantiT PicoGreen dsDNA Assay Kit (Invitrogen) and TCID 50 assays, respectively, as described elsewhere 50 . The structural integrity of packaged AdV genomes was assessed by restriction fragment length analysis (i.e. Kpn2I and BglII) of DNA isolated from the respective purified particles as described before 28, 33, 51 .
Production and characterization of Adenoviral vectors.
Transduction experiments.
Gene editing experiments were initiated by seeding DMD.Δ 45-52 and DMD. . DMD.Δ 48-50 myoblasts transduced with AdV.Cas9 EX51 served as a reference for DMD reading frame repair by a gene editing approach based on the delivery of a single RGN complex. Negative controls were provided by mock-transduced DMD.Δ 45-52 and DMD.Δ 48-50 myoblasts. Three days post-transduction, the inocula were discarded and the cells were transferred into cell culture vessels containing regular growth medium. Seven days post-transduction, genomic DNA was isolated and the intragenic DMD deletion frequencies were determined by qPCR assays as indicated below. The frequencies of targeted DSB formation in AdV.Cas9 EX51 -transduced DMD.Δ 48-50 myoblasts were assessed by TIDE analysis as indicated elsewhere 20, 52 . qPCR assays. The frequencies of DMD intragenic deletions were assessed by qPCR assays. To this end, total cellular DNA from mock-or AdV-transduced cells was extracted at 7 days post-transduction by using the DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer's instructions. Next, 5 ng of genomic DNA were diluted in 20-μ l reaction mixtures with 1 × iQ TM SYBR Green Supermix (Bio-Rad) and 150 nM of each primer. The primers were designed with the aid of the open source Primer3 program (http://frodo.wi.mit.edu/) and their sequences are specified in the Supplementary Table S6. All samples were amplified in triplicate. Parallel qPCR amplifications targeting DNA sequences located in intron 43 of the DMD locus provided for internal controls. The amplifications were carried in a CFX Connect TM Real-Time System (Bio-Rad), according to the thermal cycling protocols indicated in Supplementary Table S7 . After each run, the baseline thresholds and the estimated copy numbers were auto-calculated by Bio-Rad CFX Manager 3.1. The copy numbers of genomic short-and long-range DMD deletions were determined on the basis of standard curves using serial dilutions (ranging from Scientific RepoRts | 6:37051 | DOI: 10.1038/srep37051 2.26 × 10 to 2.32 × 10 4 copies) of AV31_jDEL.I52-I53 and AV24_jDEL.I43-I54 plasmids, respectively. For the internal control samples, standard curves were made on the basis of serial dilutions (ranging from 7.56 × 10 through 7.56 × 10 4 copies) of reference plasmid AL05_pDMD. Finally in order to estimate deletion frequencies, the copy numbers of genomic deletions were normalized, on a per-sample basis, for the copy numbers of the internal control. The data were plotted with the aid of Microsoft Office Excel 2010.
Qualitative detection of long-range DMD deletions. Genomic DNA extracted from mock-or AdV-transduced cells was subjected to PCR assays for amplifying DNA fragments spanning the expected DNA junctions formed after the coordinated action of RGN pairs. The primer sequences, PCR mixture compositions and cycling parameters are listed in the Supplementary Tables S2 and S3 . Agarose gel electrophoresis in 1× TAE buffer was performed for the detection of the resulting PCR products.
Western blot analysis. The S1 . Three days post-transduction, the various inocula were replaced by mitogen-poor differentiation medium to trigger myoblast differentiation and fusion. The differentiation medium consisted of phenol red-free DMEM supplemented with 0.05% bovine serum albumin (Sigma-Aldrich), 10 ng/ml epidermal growth factor (Sigma-Aldrich), 1 mM creatine monohydrate (Sigma-Aldrich), 50 μ g/ml uridine (Sigma-Aldrich), 100 ng/ml pyruvic acid (Sigma-Aldrich), 1× Penicillin/Streptomycin (Life Technologies) and 1× GlutaMax (Life Technologies). After 4 to 5 days in differentiation medium, the myotube-containing cultures were lysed by incubation on ice for 30 min in 50 μ l of RIPA buffer (Thermo Scientific) supplemented with a protease inhibitor cocktail (cOmplete TM Mini, Sigma-Aldrich). Next, the cell lysates were diluted in 4× sample buffer and 20× reducing agent (both from Bio-Rad) and incubated at 95 °C for 5 min. Protein samples and 15 μ l of HiMark TM Prestained Protein Standard (Thermo Scientific) were loaded in a 3-8% Criterion TM XT Tris-Acetate precast gel (Bio-Rad). The gel was placed in an ice-cooled Criterion TM Cell and was run in XT Tricine running buffer (both from Bio-Rad) first for 1 h at 75 V (0.07 A) and then for 2.5 h at 150 V (0.12 A). Subsequently, the resolved proteins were transferred with the aid of a Trans-Blot ® Turbo TM Midi PVDF pack and a Trans-Blot Turbo TM system (both from Bio-Rad), according to the manufacturer's recommendations for high molecular-weight proteins (2.5 A, 25 V, 10 min). The PVDF membrane was blocked overnight in TBS with 0,05% (v/v) Tween 20 (TBST, Thermo Scientific) supplemented with 5% (w/v) Elk milk (Campina) and subsequently was washed in TBST. Next, the membrane was incubated with a rabbit polyclonal antibody directed against dystrophin (ab15277; abcam) or against α /β Tubulin (CST #2148) diluted in TBST with 5% (w/v) Elk milk. After an overnight incubation period at 4 °C, the membrane was washed in TBST and incubated for 4 h at 4 °C with an anti-rabbit IgG secondary antibody conjugated to horseradish peroxidase (IgG-HRP; Santa Cruz) diluted in TBST. Proteins were detected by using horseradish peroxidase substrate Pierce TM ECL2 (Thermo Scientific) following the manufacturer's specifications with the aid of Super RX-N X-Ray film (Fujifilm).
The schematic representation of the Becker-like dystrophin molecules and their respective molecular weights resulting from AdV-based DMD editing procedures involving short-and long-range deletions were assembled with the aid of the eDystrophin website (http://edystrophin.genouest.org/) (ref. 53 ).
Immunofluorescence microscopy. DMD.Δ 45-52 and DMD.Δ 48-50 myoblasts were seeded and transduced with AdV.Cas9
IN43.IN54 as indicated above (Transduction experiments). Cultures of differentiated wild-type myoblasts that had been transduced with control vector AdV.gRNA S1 at an MOI of 50 IU/cell served as positive controls for dystrophin immunodetection assays, whereas exposing DMD.Δ 45-52 and DMD.Δ 48-50 myoblasts to the same vector at an MOI of 12.5 IU/cell provided for negative controls. Cultures of differentiated DMD.Δ 48-50 myoblasts that had been transduced with different MOIs of AdV.Cas9 EX51 served as additional reference samples.
Three days post-transduction, myoblast differentiation and fusion were triggered by adding mitogen-poor medium, as indicated above (western blot analysis). The myotube-containing cultures of myoblasts with wild-type, DMD.Δ 45-52 and DMD.Δ 48-50 genotypes were stained as described elsewhere 20 after 3, 4 and 5 days in differentiation medium, respectively. The applied primary antibodies were a rabbit polyclonal antibody directed against the C-terminus of dystrophin (ab15277; abcam) and the NCL-b-DG mouse monoclonal antibody specific for β -dystroglycan (clone 43DAG1/8D5; Novocastra).
